Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients).
From Unit of Cardiovascular Science, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (F.M., E.P., I.C., E.R., G.D.S.); Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (A.L.P., P.P.); Cardiovascular Research Center Aalst, OLV Hospital, Aalst, Belgium (E.B.); and Departement of Advanced Biomedical Sciences, University of Naples Federico II, Italy (E.B.). f.mangiacapra@unicampus.it.
Fabio
F
Mangiacapra
From Unit of Cardiovascular Science, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (F.M., E.P., I.C., E.R., G.D.S.); Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (A.L.P., P.P.); Cardiovascular Research Center Aalst, OLV Hospital, Aalst, Belgium (E.B.); and Departement of Advanced Biomedical Sciences, University of Naples Federico II, Italy (E.B.).
Elena
E
Panaioli
From Unit of Cardiovascular Science, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (F.M., E.P., I.C., E.R., G.D.S.); Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (A.L.P., P.P.); Cardiovascular Research Center Aalst, OLV Hospital, Aalst, Belgium (E.B.); and Departement of Advanced Biomedical Sciences, University of Naples Federico II, Italy (E.B.).
Iginio
I
Colaiori
From Unit of Cardiovascular Science, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (F.M., E.P., I.C., E.R., G.D.S.); Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (A.L.P., P.P.); Cardiovascular Research Center Aalst, OLV Hospital, Aalst, Belgium (E.B.); and Departement of Advanced Biomedical Sciences, University of Naples Federico II, Italy (E.B.).
Elisabetta
E
Ricottini
From Unit of Cardiovascular Science, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (F.M., E.P., I.C., E.R., G.D.S.); Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (A.L.P., P.P.); Cardiovascular Research Center Aalst, OLV Hospital, Aalst, Belgium (E.B.); and Departement of Advanced Biomedical Sciences, University of Naples Federico II, Italy (E.B.).
Angelo
A
Lauria Pantano
From Unit of Cardiovascular Science, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (F.M., E.P., I.C., E.R., G.D.S.); Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (A.L.P., P.P.); Cardiovascular Research Center Aalst, OLV Hospital, Aalst, Belgium (E.B.); and Departement of Advanced Biomedical Sciences, University of Naples Federico II, Italy (E.B.).
Paolo
P
Pozzilli
From Unit of Cardiovascular Science, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (F.M., E.P., I.C., E.R., G.D.S.); Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (A.L.P., P.P.); Cardiovascular Research Center Aalst, OLV Hospital, Aalst, Belgium (E.B.); and Departement of Advanced Biomedical Sciences, University of Naples Federico II, Italy (E.B.).
Emanuele
E
Barbato
From Unit of Cardiovascular Science, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (F.M., E.P., I.C., E.R., G.D.S.); Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy (A.L.P., P.P.); Cardiovascular Research Center Aalst, OLV Hospital, Aalst, Belgium (E.B.); and Departement of Advanced Biomedical Sciences, University of Naples Federico II, Italy (E.B.).
Germano
G
Di Sciascio
D000241:Adenosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077144:Clopidogrel; D003324:Coronary Artery Disease / Q000209:etiology / Q000628:therapy*; D048909:Diabetes Complications / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000077486:Ticagrelor; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine
diabetes mellitus; endothelium; platelet aggregation inhibitors